why choose us

Clinical Trials Search

Showing 10,430 of 132,366 result(s)
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

Status: NOT_YET_RECRUITING

Condition: Cutis Laxa Facialis

Interventions: Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.

Date: 2023-06-15

TMS + Exposure Therapy for Pediatric OCD

Status: NOT_YET_RECRUITING

Condition: Obsessive-Compulsive Disorder

Interventions: TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern

Date: 2023-06-15

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Status: Completed

Condition: Single Ventricle Heart Disease

Interventions: Active drug

Date: 2023-06-15

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Status: Completed

Condition: COVID-19

Interventions: Capsule administered orally after meals.

Date: 2023-06-15

Emotional Changes Between Emergency and Intensive Care Unit and On-site Counter Staffs After COVID-19 Infection

Status: Completed

Condition: Psychological Distress

Interventions: Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel

Date: 2023-06-15

Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients

Status: NOT_YET_RECRUITING

Condition: ARDS Due to Disease Caused by SARS Co-V-2

Interventions: Conversion from vv-ECMO to va-ECMO

Date: 2023-06-15

Have Physical Therapists Attitudes and Beliefs Towards Vital Assessment Changed Following the COVID-19 Pandemic?

Status: NOT_YET_RECRUITING

Condition: Vital Signs

Interventions: This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey.
This type of survey can be conducted on a represe

Date: 2023-06-15

Daratumumab for Relapsed;Refractory Primary Effusion Lymphoma

Status: NOT_YET_RECRUITING

Condition: Lymphoma, Primary Effusion

Interventions: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg;30,000 units weekly for a total of 8 weeks (8 doses

Date: 2023-06-15

Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

Status: NOT_YET_RECRUITING

Condition: GATA2

Interventions: 15 mg;kg IV three times per day starting on day +5 until approximately day +30 (+;- 2 days)

Date: 2023-06-15